Oncology and Hematology - Prova Education

Episodes 81-96 of 128

Managing Adverse Effects of Oral vs Injectable ADT in Advanced Prostate Cancer
Managing Adverse Effects of Oral vs Injectable ADT in Advanced Prostate Cancer
MinuteCE®
Managing Adverse Effects of Oral vs Injectable ADT in Advanced Prostate Cancer
0.75 program credits
- Tanya Dorff, MD
0.75 program credits
MinuteCE®
Advancing Prostate Cancer Care: Integrating Guideline Updates and Patient Preferences for Optimal ADT Management of Advanced Prostate Cancer
0.75 credits 7 episodes
- Tanya Dorff, MD
- Rana McKay, MD
0.75 credits 7 episodes
Incorporation of guideline-concordant care for first-line treatment of a patient with metastatic urothelial carcinoma
Incorporation of guideline-concordant care for first-line treatment of a patient with metastatic urothelial carcinoma
MinuteCE®
Incorporation of guideline-concordant care for first-line treatment of a patient with metastatic urothelial carcinoma
1.25 program credits
- Ignacio Duran, MD
- Sandy Srinivas, MD
1.25 program credits
Best Practices in Shared Decision Making: Selection of the Optimal ADT Regimen in mHSPC Based on Patient Preferences
Best Practices in Shared Decision Making: Selection of the Optimal ADT Regimen in mHSPC Based on Patient Preferences
MinuteCE®
Best Practices in Shared Decision Making: Selection of the Optimal ADT Regimen in mHSPC Based on Patient Preferences
0.75 program credits
- Rana McKay, MD
0.75 program credits
Emerging and Practice-Changing Directions in Gynecologic Malignances Involving Combination Therapies With Immune Checkpoint Inhibitors
Emerging and Practice-Changing Directions in Gynecologic Malignances Involving Combination Therapies With Immune Checkpoint Inhibitors
MinuteCE®
Emerging and Practice-Changing Directions in Gynecologic Malignances Involving Combination Therapies With Immune Checkpoint Inhibitors
1.00 program credit
- Susana Campos, MD, MPH
1.00 program credit
Targeted Therapy in the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
Targeted Therapy in the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
MinuteCE®
Targeted Therapy in the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
1.00 program credit
- Ritu Salani, MD, MBA
- Nicoletta Colombo, MD
1.00 program credit
Guideline Recommendations for Biomarker-Directed Therapies in Cervical Cancer
Guideline Recommendations for Biomarker-Directed Therapies in Cervical Cancer
MinuteCE®
Guideline Recommendations for Biomarker-Directed Therapies in Cervical Cancer
1.00 program credit
- Ritu Salani, MD, MBA
- Nicoletta Colombo, MD
1.00 program credit
MinuteCE®
Innovations in Oncology Learning Center From Guidelines to Practice: Gynecologic Cancer
1.00 credit 10 episodes
- Susana Campos, MD, MPH
- Nicoletta Colombo, MD
- Ritu Salani, MD, MBA
1.00 credit 10 episodes
Emerging targeted therapy combination strategies in genitourinary malignancies
Emerging targeted therapy combination strategies in genitourinary malignancies
MinuteCE®
Emerging targeted therapy combination strategies in genitourinary malignancies
1.25 program credits
- Ignacio Duran, MD
1.25 program credits
Emerging immunotherapy combination strategies in genitourinary malignancies
Emerging immunotherapy combination strategies in genitourinary malignancies
MinuteCE®
Emerging immunotherapy combination strategies in genitourinary malignancies
1.25 program credits
- Sandy Srinivas, MD
1.25 program credits
Best Practices in Shared Decision-Making: Discussing ADT Regimens in mHSPC With Your Patient
Best Practices in Shared Decision-Making: Discussing ADT Regimens in mHSPC With Your Patient
MinuteCE®
Best Practices in Shared Decision-Making: Discussing ADT Regimens in mHSPC With Your Patient
0.75 program credits
- Rana McKay, MD
0.75 program credits
Implementing Guideline-Concordant Care Into a Targeted Therapy Approach for Patients With Platinum-Resistant Ovarian Cancer
Implementing Guideline-Concordant Care Into a Targeted Therapy Approach for Patients With Platinum-Resistant Ovarian Cancer
MinuteCE®
Implementing Guideline-Concordant Care Into a Targeted Therapy Approach for Patients With Platinum-Resistant Ovarian Cancer
1.00 program credit
- Susana Campos, MD, MPH
- Ritu Salani, MD, MBA
1.00 program credit
Emerging and practice-changing directions in NSCLC within the perioperative and locally advanced settings
Emerging and practice-changing directions in NSCLC within the perioperative and locally advanced settings
MinuteCE®
Emerging and practice-changing directions in NSCLC within the perioperative and locally advanced settings
1.00 program credit
- Luis Paz-Ares, MD, PhD
- Helena Yu, MD
- Matthew Gubens, MD, MS
1.00 program credit
MinuteCE®
Innovations in Oncology Learning Center From Guidelines to Practice: Lung Cancer
1.00 credit 10 episodes
- Luis Paz-Ares, MD, PhD
- Helena Yu, MD
- Matthew Gubens, MD, MS
1.00 credit 10 episodes
Incorporation of guidelines-concordant care for advanced NSCLC with second-line targeted therapies
Incorporation of guidelines-concordant care for advanced NSCLC with second-line targeted therapies
MinuteCE®
Incorporation of guidelines-concordant care for advanced NSCLC with second-line targeted therapies
1.00 program credit
- Luis Paz-Ares, MD, PhD
- Helena Yu, MD
- Matthew Gubens, MD, MS
1.00 program credit
Guidelines-recommended first-line treatment with immunotherapy-based regimens in PD-L1- positive metastatic NSCLC
Guidelines-recommended first-line treatment with immunotherapy-based regimens in PD-L1- positive metastatic NSCLC
MinuteCE®
Guidelines-recommended first-line treatment with immunotherapy-based regimens in PD-L1- positive metastatic NSCLC
1.00 program credit
- Luis Paz-Ares, MD, PhD
- Helena Yu, MD
- Matthew Gubens, MD, MS
1.00 program credit

6/8